ImmuCell Corporation (NASDAQ:ICCC) Files An 8-K Entry into a Material Definitive Agreement

ImmuCell Corporation (NASDAQ:ICCC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.  Entry into a Material Definitive Agreement

On September 12, 2019, ImmuCell Corporation (the Company) entered into a lease covering approximately 14,300 square feet of office and warehouse space effective approximately November 1, 2019. The space will be utilized to enable the Company’s plan to increase the production capacity of the First Defense® product line. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. 


Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits relating to Item 1.01 shall be deemed to be furnished, and not filed:

99.1 Press Release of ImmuCell Corporation dated September 17, 2019.
99.2 Indenture of lease for premises located in Portland, Maine between TVP, LLC as Landlord and ImmuCell Corporation as Tenant, dated as of September 12, 2019.

To view the full exhibit click here

Story continues below

About ImmuCell Corporation (NASDAQ:ICCC)

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company’s lead product, First Defense, is manufactured from cows’ colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

An ad to help with our costs